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Primary intracranial myxoﬁbrosarcoma is exceedingly
rare, with less than 10 cases published. We present a
case of a 23-year-old man with previous history of a
primary low grade myxoﬁbrosarcoma of the left parietal-
occipital convexity resected in March 1999. He
subsequently underwent several interventions for
multiple local recurrent disease until March 2004.
At that time, complete remission was documented.
About 8 years later, in February 2012, the patient was
admitted to the emergency room with refractory acute
pulmonary oedema. On work up, sustained
monomorphic ventricular tachycardia and hyperechoic
myocardial mass with invasion of the right ventricular
cavity were detected. Electrical cardioversion was
unsuccessful and irreversible cardiac arrest followed. The
autopsy conﬁrmed multiple bilateral lung metastases,
malignant pulmonary embolism and myocardial invasion
by the primary tumour, with intracavitary cardiac
thrombosis and absence of intracranial disease. To the
best of our knowledge, this is the ﬁrst report of
extracranial metastases of this neoplasm.
BACKGROUND
Cardiac neoplasms are rare, and mostly metastatic
in origin. Cardiac metastases are found at autopsy
in 6–20% of patients with malignant neoplasms.1
More than one-third (36%) of cardiac metastases
originate from lung cancer. Leukaemia, lymphoma
and Kaposi sarcoma account for 20% of cardiac
metastases, breast carcinoma for 7% and oesopha-
geal carcinoma for 6%.2 Cardiac metastases are the
immediate cause of death in as many as one-third
of the cases in which they occur.3 Usually, the
related symptoms are insidious in young and
middle-aged patients.4 Symptoms may be speciﬁc,
such as pericardial effusion with tamponade,
arrhythmias, valvular dysfunction, intracardiac
blood ﬂow abnormalities, congestive heart failure,
dyspnoea, chest pain, syncope, haemoptysis and
sudden cardiac death. Patients may also present
with other symptoms related with the primary
tumour.5 Myxoﬁbrosarcoma (MFS) is a tumour
comprising malignant spindle cells in a myxoid
stroma.6 Clinically, MFS tends to occur as masses
in the proximal limb girdles of elderly patients
where they may involve skeletal muscle, fascia, sub-
cutaneous adipose and through their propensity for
inﬁltrative growth, the dermis.7 Sarcomas metasta-
sise mainly to the lungs, but they may also involve
the liver, lymph nodes, bone and brain. In the lit-
erature, there are only three reports of intracerebral
metastases from MFS.8 We report a different
pattern of a primary intracranial MFS with extra-
cranial metastases. The rarity of these tumours
leads to a paucity of data and experience regarding
their management, and there is no consensus on
the best treatment strategy.4 5 To our knowledge,
this is the ﬁrst report of a primary intracranial MFS
with cardiac metastases (particularly on the right
ventricle) in a patient with long survival after the
initial diagnosis. The purpose of this report is to
present this unusual case.
CASE PRESENTATION
In February 2012, a 23-year-old man was admitted
to the emergency room with a severe unspeciﬁed
chest pain, lasting more than 24 h, inconstant,
without relief symptoms, associated with shortness
of breath, cold sweats and dizziness. At the time, he
was under antibiotics for a lower respiratory infec-
tion. A month before, a right inferior pulmonary
lobectomy had been performed on suspicion of a
late lung relapse of a primary central nervous
system (CNS) tumour, which was not conﬁrmed
histologically.
Thirteen years prior, at the age of 10 years, and
with an unremarkable medical and family history,
he had undergone a complete excision of an extra-
axial lesion in the left parietal-occipital convexity.
At the time, histological examination revealed a
low-grade MFS, characterised by ﬁbrous and
myxoid areas with low mitotic index. Neither haem-
orrhage nor necrosis was present. The neoplasm
expressed immunoreactivity for vimentin and CD34
(focal); epithelial membrane antigen (EMA), S100,
smooth muscle actin (SMA) and desmin were nega-
tive (ﬁgure 1A and B). Pathology was reviewed by
experts in CNS and Soft Tissues tumours at the
Mayo Clinic’s Pathology Department in Rochester,
USA, conﬁrming the diagnosis.
The patient had remained asymptomatic until
February 2000, when local relapse was detected
(ﬁgure 2). A second surgery was then carried out,
with similar histological diagnosis, followed by adju-
vant external-beam radiotherapy (39.6 Gy in 32
fractions). Shortly after, brain magnetic resonance
imaging (MRI) documented total remission. About
1 year later, a second small local recurrence was
detected. In June 2002, a third surgery was per-
formed with partial removal, since the parasagittal
lesion was not amenable to resection. Again, the
histological diagnosis was identical. Unfortunately,
the patient developed rapid symptomatic disease
progression, with throbbing headaches, a small
visual ﬁeld defect and nausea. At that time, the
patient presented a poor response to symptomatic
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treatment, including corticosteroids. In October 2002, he was
submitted to a fourth surgery with subtotal resection of the
lesion, with the same histology. Thereafter, he was treated in
another institution in Spain, where fractionated external beam
stereotactic radiotherapy (SRT) (57.6 Gy in 32 fractions) was per-
formed, which was completed in February 2003. A tumour
regression of about 80% was documented, with a residual hetero-
geneous lesion involving the posterior portion of the superior
sagittal sinus and parietal-occipital left side. In December 2003,
the patient underwent surgery for the ﬁfth time, after new
disease progression at the same location. Again, the resection was
incomplete, with persistent disease adherent to the venous drain-
age system. At that time, the patient was 15 years old, and the
tumour board decided to perform a second SRT scheme (45 Gy
in 25 fractions), which was completed in March 2004. The
response evaluation by brain MRI (ﬁgure 3A and B), with single-
voxel spectroscopy sequence included, conﬁrmed complete
remission (ﬁgure 3A and B). Despite this optimal response, rele-
vant neurological sequelae related to the treatment were docu-
mented: the visual ﬁeld defect, which worsened on
discontinuation of corticosteroids, focal epilepsy and mild right
hemiparesis with crural predominance.
About 8 years later, in December 2011, the patient reported of
persistent dry cough and low-grade fever. He reported neither
dyspnoea, pleuritic pain, tiredness, profuse sweating, haemopty-
sis, anorexia nor weight loss. There were no obvious infection
locations other than the respiratory tract. The chest X-ray
showed lower right lobe opacity with pleural effusion (ﬁgure 4).
Laboratory ﬁndings included: haemoglobin 14.1 g/dL, platelet
count 362×109/L, total leukocyte count 11.1×109/L, neutro-
phils 63.8×109 (57.5%), lymphocytes 17.8×109 (16%),
erythrocyte sedimentation rate 35.0, C reactive protein 6.7 mg/
dL and lactate dehydrogenase 264 UI/L. Culture tests were nega-
tive. Symptoms were initially interpreted as a lower respiratory
infection and the patient was treated with antibiotics. Brain MRI
excluded recurrence. Two weeks later and despite some clinical
improvement, a bronchoscopy was conducted to clarify the clin-
ical picture. This examination showed partial occlusion of the
right bronchus and extrinsic compression of the basal pyramid.
The possibility of a late distant recurrence was admitted and the
patient was submitted to right inferior lung lobectomy. However,
no evidence of tumour tissue was observed and only a necrotising
inﬂammatory granulomatous process was identiﬁed (negative
microbiological tests, including Koch’s bacillus (BK) test and
Löwenstein culture).
One month later, he presented with a similar clinical presenta-
tion, with cough, low-grade fever and pleuritic pain on the right
side. Thoracic computerised tomography (CT) scan revealed
moderate right pleural effusion, septate pneumothorax related
to previous lung surgery, as well as multiple suspicious nodules
in both lungs (ﬁgure 5). He was admitted to our Institution,
diagnosed as having a lower respiratory infection, and treated
with antibiotics and supportive medication. However, the
patient did not improve and a few days later, he was transferred
to the emergency department. At the time, he was tachycardic
(105 bpm), his blood pressure was 150/90 mm Hg and a para-
doxical pulse was present. He had mild jugular distension.
Chest X-ray revealed a right pleural effusion with an ipsilateral
conﬂuent heterogeneous opacity as well as other bilateral
nodules. Electrocardiogram (ECG) and echocardiogram revealed
a sustained monomorphic ventricular tachycardia with left
bundle branch block, hyperechoic myocardial mass with inva-
sion of the right ventricular cavity and a mild pericardial effu-
sion (ﬁgure 6 and video 1). Troponine Twas slightly above the
upper limit: 0.057 (<0.5 ng/mL); D-dimers increased: 932.0
(<230 ng/mL); and arterial blood gases were: pH 7.44, pCO2
28.4 mm Hg, pO2 102.3 mm Hg, HCO3 18.8, peripheral
Figure 1 (A) H&E staining, magniﬁcation ×40. (B) Vimentin staining
conﬁrming mesenchymal origin of the tumour, magniﬁcation ×100.
Histological examination revealed ﬁbrous and myxoid areas with abrupt
transition between both. Myxoid areas had loosely whorled growth
pattern around blood vessels, variable cellularity and variable amount
of myxoid matrix. They were composed of spindle cells with ovoid
nuclei and little cytoplasm. Fibrous areas had low to moderate
cellularity and bland spindle cells with minimal pleomorphism and no
mitosis. The neoplasm expressed immunoreactivity for vimentin.
Figure 2 MRI T1 sagittal section showing a nodular heterogeneous
lesion in a cortical-subcortical left occipital location.
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saturation 97.9% (FiO2=21%). Owing to the rapid deterior-
ation of the clinical condition with refractory acute pulmonary
oedema, the patient was transferred to the cardiology intensive
care unit and emergency manoeuvres were initiated. Electrical
cardioversion was attempted with 200, 300 and 360 J.
Unfortunately, the situation evolved into an irreversible cardiac
arrest.
OUTCOME AND FOLLOW-UP
The patient died 2 h after admission, with an irreversible
cardiac arrest, on 24 February 2012. The autopsy conﬁrmed
multiple bilateral lung metastases, bilateral pulmonary tumour
embolism, pericardium and myocardial invasion by primary
tumour, with intracavitary cardiac thrombosis and no evidence
of intracranial recurrence.
DISCUSSION
MFS, ﬁrst described by Angervall et al,6 is a variant of a group
of malignant ﬁbrous histiocytomas (MFH), a highly heteroge-
neous group of soft tissue neoplasms.9 In fact, because ultra-
structural studies have shown a ﬁbroblastic differentiation, today
it is considered a distinct tumour, with myxoid features, myo-
genic differentiation with immunoreactivity to SMA and a
better prognosis than other cellular subtypes of MFH.10 11 MFS
is the second most frequent subtype, representing 20% of all
cases. In our case, the neoplasm histology showed ﬁbrous and
myxoid areas with abrupt transition between both. The myxoid
areas had a loosely whorled growth pattern around blood
vessels, variable cellularity and a variable amount of myxoid
matrix. They were composed of spindle cells with ovoid nuclei
and little cytoplasm. Variable nuclear pleomorphism and mitotic
ﬁgures were present in the nodules; the more proliferative
showed 8 mitosis/10 HPF. Fibrous areas had low to moderate
cellularity and bland spindle cells, with minimal pleomorphism
and no mitosis. Neither haemorrhage nor necrosis was present.
The neoplasm expressed immunoreactivity for vimentin and
CD34 (focal); EMA, S100, SMA and desmin were negative.
Recurrences showed more myxoid areas, more cellularity and
more cellular pleomorphism. Differential diagnosis between
low-grade MFS and low-grade ﬁbromyxoid sarcoma was
recently aided by the absence of the chromosomal translocation,
t(7;16)(q34;p11) with fusion gene FUS-CREB3L2 (BBF2H7),
searched for but not found in this tumour.12
An intracranial location is extremely rare and, to the best of
our knowledge, only four other cases have been published. One
of the cases reported was of a 19-year-old woman, in whom the
was located in the temporal bone, with endocranial extension,
and resembling a meningioma on imaging.13 Surgery and
Figure 3 (A and B): MRI T2 axial
section revealing complete disease
remission. The single-voxel
spectroscopy sequence showing,
bilaterally, signal changes in white
matter of the parietal-occipital lobe
due to iatrogenic causes.
Figure 4 Plain chest radiography showing lower right lobe opacity
with pleural effusion.
Figure 5 Thoracic CT showing right pleural effusion, septate
pneumothorax and multiple nodules in both lungs.
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adjuvant chemotherapy was performed. At 18 months of
follow-up the patient was doing well with no evidence of
disease.
Another case was that of a 21-year-old woman with an exten-
sive frontoparietal-occipital lesion. After a ﬁrst gross total resec-
tion, the patient had two recurrences within a time frame of
2.5 years, with increasing tumour extent and histological grade,
permitting only decompression during the third surgery.14 One
other case occurred in a 9-year-old boy. Nine months after
surgery, local recurrence was noted and surgery performed.
With 6 months of follow-up, the patient was well and with no
recurrence.10
A case of MFS secondary to radiation was also documented
in a 28-year-old man, 17 years after the treatment of basal
ganglia germinoma.15 Long-term follow-up details are unknown
for this patient.
The differential diagnosis of intracardiac mass lesions includes
benign and malignant tumours, such as a thrombus, vegetation
and foreign bodies. However, intracardiac metastases, even
though rare, should also be included in the differential diagno-
sis, as well as infectious and non-bacterial thrombotic or maran-
tic endocarditis.16
Reﬂecting the age distribution of malignant diseases, cardiac
metastases predominantly occur in patients in the sixth and
seventh decade of life. There is no sex preference and they
mostly appear in disseminated disease, as solitary metastases are
very rare.17 Metastases may reach the heart via the lymphatic or
the haematogenous route, or by transvenous extension.
Lymphatic spread usually originates from pericardial metastases
while myocardial metastases usually arise from a haematogenous
route. In our case, at the time of necropsy, extensive multiple
and bilateral pulmonary metastases were documented as well as
multiple instances of mediastinic nodal involvement. It is rea-
sonable to assume that tumour cells from the right cardiac
chambers were being released from the heart and spread into
both lungs, over time.
On the other hand, there was evidence of invasion of the par-
ietal pericardium of the right ventricle by the tumour itself.
Metastases to the epicardium are most commonly the result of
direct invasion by an intrathoracic or mediastinal tumour, retro-
grade lymphatic spread through tracheal or bronchomediastinal
lymphatic channels or secondary involvement of the pericar-
dium through spread from myocardial or epicardial metasta-
ses.16 Furthermore, the hypothesis that tumour cells travelled
from the intracranial venous system to the right cardiac cham-
bers, where they would deposit for several years until clinical
evidence of cardiac involvement, seems to be remote.
Cardiac tumours are generally asymptomatic, with most being
detected following diagnostic investigation of an unrelated
problem or in staging of a recently diagnosed primary tumour.
Obviously, the symptoms differ greatly according to the most
heavily involved site.18 When they grow, the most common clin-
ical manifestations are the result of large pericardial effusion,
heart failure, obstruction of cardiac chambers or embolic phe-
nomena. Cardiac tumours can also lead to rhythm disturbances,
especially in atrioventricular conduction, as well as non-speciﬁc
changes on the ECG, particularly ST-segment and T-wave altera-
tions. Although less common, invasion of the myocardium can
cause sustained ST-segment elevation, mimicking acute trans-
mural myocardial infarction.19 Interestingly, there is no strong
correlation between the extent of cardiac metastases and the
clinical picture.20 Similar to most patients, our patient showed
symptoms of congestive heart failure and embolisation.21
Autopsy conﬁrmed multiple bilateral lung metastases, malignant
pulmonary embolism and myocardial invasion by the primary
tumour, with intracavitary cardiac thrombosis. Generally, the
clinical pattern tends to be proportional to the degree of myo-
cardial inﬁltration, or related to the wall inﬁltration site. Indeed,
tumours spreading more extensively to the pericardium or
cardiac chambers may give a dramatic presentation, causing
medical emergencies. Whenever the right heart is involved, the
interventricular septum is likely to be involved in the process,
and the conduction system may be compromised.20 In our
patient, the cardiac invasion led to a sustained monomorphic
ventricular tachycardia with left bundle branch block, as docu-
mented when the patient was admitted to the emergency room.
The evidence of cardiac metastasis has clear prognostic impli-
cations. It depends on several factors, such as the primitive
tumour, the extent of the disease and the potential curative
management of cardiac involvement.17 20 Owing to the rarity of
the case, no speciﬁc reports are available for patients with
cardiac metastases from intracranial MFS. According to some
reports of other primitive tumours, an average survival period
after the diagnosis of cardiac metastases has been approximately
5.5 months.22 Furthermore, it is very important to know that,
in patients with cancer with clinical symptoms of heart involve-
ment, metastatic cardiac deposits must always be considered in
the differential diagnosis. In fact, clinicians should be alert to
the possibility of cardiac metastases in a patient with, or even
Figure 6 Right ventricle inﬂow view: intracardiac mass in the free
wall of the right ventricle, near the posterior leaﬂet of the tricuspid
valve.
Video 1 Emergency department echocardiogram, right ventricle
inﬂow view.
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without, clinical symptoms. To note, cardiac involvement does
not only have prognostic implications: even when curative
therapy is not available, palliative measures may improve the
quality of life of affected patients. However, one must keep in
mind that, in some cases, there is no time to offer any kind of
palliative treatment and cardiac involvement is not noticed until
after death.17
The case presented is about cardiac metastases from MFS, a
rare entity that has seldom been reported in the literature.
Unfortunately, the diagnosis of cardiac metastases was only sus-
pected when cardiac symptoms led the patient to the emergency
department with rapid clinical deterioration. Deﬁnitive diagno-
sis is frequently conﬁrmed only after death, as happened in this
case.
Learning points
▸ The rare occurrence of primary intracranial
myxoﬁbrosarcoma (MFS) leads to a paucity of data and
experience regarding its management.
▸ We report the ﬁrst case of primary intracranial MFS with
extracranial metastases and, particularly, in the right
ventricle, an even rarer phenomenon. This required an
independent external conﬁrmation of the histological
diagnosis in another specialised centre.
▸ The process of spreading of the metastases to the heart
remains unclear: whether by direct invasion, retrograde
lymphatic spread of lung or mediastinal metastases, by
secondary involvement of the pericardium through
myocardial or epicardial metastases or, the most remote
hypothesis, related to cardiac deposition of the tumour cells
migrating from the intracranial venous system.
▸ Despite the long disease-free survival obtained with multiple
treatments, one cannot neglect the neurological sequelae
that impacted on the patient’s quality of life.
Acknowledgements The authors are most grateful to the deceased and honoured
colleague from Mayo Clinic’s Pathology Department, Dr Bernd Scheithauer, for
revising the pathology, and to Dr Duarte Salgado, the neurologist who closely
followed the evolution of the patient. The authors also thank ITClinical for the
linguistic revision; Samanta McMurray for photography and digital work; and Dr
Pedro Ferreira for cardiac imaging and video; and, ﬁnally, a special thanks to the
patient’s parents, Teresa Santos and Francisco Patrício, for their indispensable
collaboration.
Contributors DAC, PB, EG and MM equally participated in writing and reviewing
the case report.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1 Pinho T, Rodrigues-Pereira P, Araújo V, et al. Cardiac metastasis of melanoma as
ﬁrst manifestation of disease. Rev Port Cardiol 2009;5:633–9.
2 Chiles C, Woodard PK, Gutierrez FR, et al. Metastatic involvement of the heart and
pericardium: CT and MR Imaging. Radiographics 2001;21:439–49.
3 Hallahan DE, Vogelzang NJ, Borow KM, et al. Cardiac metastases from soft-tissue
sarcomas. J Clin Oncol 1986;4:1662–9.
4 Agaimy A, Rösch J, Weyand M, et al. Primary and metastatic cardiac sarcomas: a
12-year experience at a German heart center. Int J Clin Exp Pathol 2012;5:928–38.
5 Takenaka S, Hashimoto N, Araki N, et al. Eleven cases of cardiac metastases from
soft-tissue sarcomas. Jpn J Clin Oncol 2011;41:514–18.
6 Angervall L, Kindblom LG, Merck C. Myxoﬁbrosarcoma. A study of 30 cases. Acta
Pathol Microbiol Scand A 1977;85A:127–40.
7 Fanburg-Smith JC, Spiro IJ, Katapuram SV, et al. Inﬁltrative subcutaneous malignant
ﬁbrous histiocytoma: a comparative study with deep malignant ﬁbrous histiocytoma
and an observation of biologic behavior. Ann Diagn Pathol 1999;3:1.
8 Wernhart S, Woernle CM, Neidert MC, et al. A deeply seated brain metastasis from
a primary myxoﬁbrosarcoma: case report. Clin Neurol Neurosurg 2013;115:2296–8.
9 Castronovo C, Arrese JE, Quatresooz P, et al. Myxoﬁbrosarcoma: a diagnostic pitfall.
Rare Tumors 2013;5:e60.
10 Buccoliero AM, Castiglione F, Garbini F, et al. Primary cerebral myxoﬁbrosarcoma:
clinical, morphologic, immunohistochemical, molecular, and ultrastructural study of
an infrequent tumor in an extraordinary localization. J Pediatr Hematol Oncol
2011;33:e279–83.
11 Al-Agha OM, Igbokwe AA. Malignant ﬁbrous histiocytoma: between the past and
the present. Arch Pathol Lab Med 2008;132:1030–5.
12 Storlazzi CT, Mertens F, Nascimento A, et al. Fusion of the FUS and BBF2H7 genes
in low grade ﬁbromyxioid sarcoma. Hum Mol Genet 2003;12:2349–58.
13 Nakayama K, Nemoto Y, Inoue Y, et al. Malignant ﬁbrous histiocytoma of the
temporal bone with endocranial extension. AJNR Am J Neuroradiol 1997;18:331–4.
14 Majumdar K, Mandal S, Saran RK, et al. Recurrent intracranial myxoﬁbrosarcoma
presenting as an extensive fronto-parieto-occipital SOL: an unusual sarcoma of
meningeal origin. Clin Neurol Neurosurg 2013;115:354–8.
15 Kuo JR, Chio CC, Wang CC, et al. Radiation-induced intra- and extra-cranial
high-grade myxoﬁbrosarcoma with tumor bleeding. J Clin Neurosci
2008;15:1151–4.
16 Bussani R, De-Giorgio F, Abbate A, et al. Cardiac metastases. J Clin Pathol
2007;60:27–34.
17 Reynen K, Kockeritz U, Strasser RH. Metastases to the heart. Ann Oncol
2004;15:375–81.
18 Vaitkus PT, Herrmann HC, LeWinter MM. Treatment of malignant pericardial
effusion. JAMA 1994;272:59–64.
19 Goldberg AD, Blankstein R, Padera RF. Tumors metastatic to the heart. Circulation
2013;128:1790–4.
20 Katalinic D, Stern-Padovan R, Ivanac I, et al. Symptomatic cardiac metastases of
breast cancer 27 years after mastectomy: a case report with literature review—
pathophysiology of molecular mechanisms and metastatic pathways, clinical aspects,
diagnostic procedures and treatment modalities. World J Surg Oncol 2013;11:14.
21 Perchinsky MJ, Lichtenstein SV, Tyers GF. Primary cardiac tumors: forty years’
experience with 71 patients. Cancer 1997;79:1809–15.
22 Ohnishi M, Niwayama H, Miyazawa Y, et al. Echocardiography in patients with
malignant metastatic neoplasms of the heart and great vessels. J Cardiol
1990;20:377–84.
Copyright 2016 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit
http://group.bmj.com/group/rights-licensing/permissions.
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.
Become a Fellow of BMJ Case Reports today and you can:
▸ Submit as many cases as you like
▸ Enjoy fast sympathetic peer review and rapid publication of accepted articles
▸ Access all the published articles
▸ Re-use any of the published material for personal use and teaching without further permission
For information on Institutional Fellowships contact consortiasales@bmjgroup.com
Visit casereports.bmj.com for more articles like this and to become a Fellow
Costa DA, et al. BMJ Case Rep 2016. doi:10.1136/bcr-2015-214052 5
Rare disease
